This database contains 219 studies, archived under the term: "complications"
Click here to filter this large number of results.
Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress
Richard, Edo,
Van den Heuvel, Esther,
Moll van Charante, Eric P.,
Achthoven, Lenny,
Vermeulen, Marinus,
Bindels, Patrick J.,
van Gool, Willem A.
Background and Purpose: Cardiovascular risk factors are associated with an increased risk of dementia. Treatment of hypertension and hypercholesterolemia is associated with a decrease in incident dementia. Whether interventions aimed at cardiovascular risk factors in late life also reduce dementia risk is unknown. Here, we report the outline of a pragmatic study that will attempt […]
Addenbrooke’s Cognitive Examination validation in Parkinson’s disease
Reyes, M. A.,
Perez-Lloret, S.,
Roldan Gerschcovich, E.,
Martin, M. E.,
Leiguarda, R.,
Merello, M.
Background: There is a clear need for brief, sensitive and specific cognitive screening instruments in Parkinson’s disease (PD).; Objectives: To study Addenbrooke’s Cognitive Examination (ACE) validity for cognitive assessment of PD patient’s using the Mattis Dementia Rating Scale (MDRS) as reference method. A specific scale for cognitive evaluation in PD, in this instance the Scales […]
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia
Mizukami, Katsuyoshi,
Asada, Takashi,
Kinoshita, Toru,
Tanaka, Katsuaki,
Sonohara, Kazuki,
Nakai, Ryuhei,
Yamaguchi, Kiyoshi,
Hanyu, Haruo,
Kanaya, Kiyoshi,
Takao, Tetsuya,
Okada, Masakatsu,
Kudo, Sumio,
Kotoku, Hayato,
Iwakiri, Masahiko,
Kurita, Hirofumi,
Miyamura, Toshihiro,
Kawasaki, Yosuke,
Omori, Koji,
Shiozaki, Kazumasa,
Odawara, Toshinari,
Suzuki, Tatsuya,
Yamada, Shizuru,
Nakamura, Youichi,
Toba, Kenji
The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer’s disease (AD) (including mixed-type dementia) or dementia with Lewy bodies. Patients were randomly assigned to group A (TJ-54 treatment in period I […]
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H.,
Edland, S. D.,
Teng, E.,
Tingus, K.,
Petersen, R. C.,
Cummings, J. L.
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
Lloret, Ana,
Badía, Mari-Carmen,
Mora, Nancy J.,
Pallardó, Federico V.,
Alonso, Maria-Dolores,
Viña, Jose
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]